ARCA Discovery has found a way to position beta blockers-notably, bucindolol, which it has in-licensed--as heart failure drugs, using a molecular diagnostic to identify up front the patients who would have a good response and to eliminate those who'd have an adverse effect from the drug.
1200 17th Street
Suite 620
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.
